Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer

The majority of patients with castrate-resistant prostate cancer will have metastatic disease at the time of diagnosis. Investigative efforts on new therapeutics for this patient population have improved with the development of androgen signaling inhibitors, such as abiraterone and enzalutamide, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kase, Adam M, Copland III, John A, Tan, Winston
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576355/
https://www.ncbi.nlm.nih.gov/pubmed/33116629
http://dx.doi.org/10.2147/OTT.S266085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576355/
https://www.ncbi.nlm.nih.gov/pubmed/33116629
http://dx.doi.org/10.2147/OTT.S266085

Ejemplares similares